CSPCY
Get informed when a big investor buys or sells
+ FollowOvervalued by 44.9% based on the discounted cash flow analysis.
| Market cap | $10.43 Billion |
|---|---|
| Enterprise Value | $5.10 Billion |
| Dividend Yield | $0.07 (3.31%) |
| Earnings per Share | $1.32 |
| Beta | 0.73 |
| Outstanding Shares | 2,881,316,000 |
| P/E Ratio | 18.89 |
|---|---|
| PEG | -232.6 |
| Price to Sales | 0.28 |
| Price to Book Ratio | 0.28 |
| Enterprise Value to Revenue | 0.14 |
| Enterprise Value to EBIT | 0.66 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.04 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This powerful committee controls taxation, trade, and entitlement spending (like Medicare). Tax policy directly impacts corporate profitability, Medicare pricing significantly affects drug revenue, and trade policy impacts global supply chains for an international pharmaceutical company.
This committee directly regulates the Food and Drug Administration (FDA), which is the primary regulatory body for pharmaceutical drug approval, manufacturing standards, and post-market surveillance. It also influences NIH funding.
This committee has direct oversight over intellectual property (patents), which is foundational to the pharmaceutical industry. Its role in antitrust enforcement also directly impacts mergers, competition, and drug pricing practices.